藥物輸送裝置市場－全球產業規模、佔有率、趨勢、機會和預測，按應用、給藥途徑、最終用戶、地區和競爭格局分類，2020-2030年預測

2024年全球藥物輸送裝置市場規模為2,613.2億美元，預計2030年將以7.91%的複合年成長率成長至4,126.6億美元。藥物輸送裝置是專門設計的醫療技術，旨在以可控和最佳化的方式將治療物質輸送到人體，涵蓋注射、口服、透皮和吸入等多種給藥途徑。市場擴張的主要促進因素是全球慢性病盛行率的上升，這些疾病需要長期藥物管理，以及對以患者為中心的護理解決方案（包括自我給藥）日益成長的需求。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球藥物輸送設備市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依應用領域（癌症、心血管疾病、糖尿病、傳染病、其他應用）
  • 依給藥途徑（注射、外用、眼用、其他）
  • 按最終使用者（醫院、門診手術中心、其他）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美藥物傳輸設備市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲藥物輸送設備市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區藥物傳輸設備市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲藥物傳輸設備市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲藥物輸送設備市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球藥物輸送設備市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Bayer AG
• Becton, Dickinson and Company
• Altaris Capital Partners, LLC
• Holozymes Inc. (Antares Pharma Inc.)
• GlaxoSmithKline PLC
• Teva Pharmaceutical Industries Ltd

第16章：策略建議

第17章調查會社について,免責事項

The Global Drug Delivery Devices Market , valued at USD 261.32 Billion in 2024, is projected to experience a CAGR of 7.91% to reach USD 412.66 Billion by 2030. Drug delivery devices are specialized medical technologies engineered to administer therapeutic substances to the body in a controlled and optimized manner, encompassing various routes such as injectable, oral, transdermal, and inhalation systems. The market's expansion is significantly driven by the increasing global prevalence of chronic diseases requiring long-term medication management and a growing demand for patient-centric care solutions, including self-administration.

Key Market Drivers

The increasing global burden of chronic diseases significantly propels the demand for drug delivery devices, as effective long-term management of conditions like diabetes, cardiovascular diseases, and cancer necessitates reliable and often specialized administration methods. This demographic shift towards an older population with higher rates of comorbidities fuels the need for advanced solutions capable of precise dosing and improved patient adherence across various care settings, including home care. According to the World Health Organization's "Noncommunicable diseases" fact sheet, in 2021, 43 million people died from an NCD, accounting for 75% of non-pandemic-related deaths globally, underscoring the widespread need for effective therapeutic interventions delivered efficiently via modern devices.

Key Market Challenges

The complex and evolving regulatory landscape across different regions presents a significant impediment to the growth of the Global Drug Delivery Devices Market. Varying requirements for product development, clinical trials, and post-market surveillance introduce substantial unpredictability and complexity for manufacturers. This intricacy often leads to extended approval timelines and increased development expenditures, particularly for innovative combination products that integrate drugs and devices.

Key Market Trends

The rapid expansion of home-based and self-administration devices marks a transformative shift in healthcare delivery, enabling patients to manage treatments independently beyond conventional clinical settings. This evolution is primarily driven by growing demand for convenience, cost efficiency, and improved treatment adherence, particularly in chronic disease management. These solutions include user-friendly technologies such as pre-filled syringes, auto-injectors, and patch pumps, which simplify drug administration and improve the overall patient experience. Reflecting this structural change, MedTech Europe projects that the home-care segment will grow at a compound annual growth rate of 12.4% within the European medical devices market from 2025 to 2033, highlighting the accelerating transition toward decentralised care models. This momentum is further reinforced by strategic investments from leading manufacturers; for instance, Medtronic expanded 11 production lines for insulin pumps in Ireland in 2023, demonstrating its commitment to scaling capacity in response to rising demand for self-administered diabetes management solutions.

Key Market Players

• Pfizer Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Johnson and Johnson
• Bayer AG
• Becton, Dickinson and Company
• Altaris Capital Partners, LLC
• Holozymes Inc. (Antares Pharma Inc.)
• GlaxoSmithKline PLC
• Teva Pharmaceutical Industries Ltd

Report Scope:

In this report, the Global Drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Delivery Devices Market , By Application:

• Cancer
• Cardiovascular
• Diabetes
• Infectious Diseases
• Other Applications

Drug Delivery Devices Market , By Route of Administration:

• Injectable
• Topical
• Ocular
• Others

Drug Delivery Devices Market , By End User:

• Hospitals
• Ambulatory Surgical Centers
• Others

Drug Delivery Devices Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Drug Delivery Devices Market .

Available Customizations:

Global Drug Delivery Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug Delivery Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Application (Cancer, Cardiovascular, Diabetes, Infectious Diseases, Other Applications)
  • 5.2.2. By Route of Administration (Injectable, Topical, Ocular, Others)
  • 5.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Drug Delivery Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Application
  • 6.2.2. By Route of Administration
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug Delivery Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Application
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Drug Delivery Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Application
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Drug Delivery Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Application
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By End User

7. Europe Drug Delivery Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Application
  • 7.2.2. By Route of Administration
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug Delivery Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Application
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By End User
  • 7.3.2. France Drug Delivery Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Application
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Drug Delivery Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Application
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Drug Delivery Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Application
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Drug Delivery Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Application
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By End User

8. Asia Pacific Drug Delivery Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Application
  • 8.2.2. By Route of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Drug Delivery Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Application
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. India Drug Delivery Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Application
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Drug Delivery Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Application
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Drug Delivery Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Application
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Drug Delivery Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Application
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By End User

9. Middle East & Africa Drug Delivery Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Application
  • 9.2.2. By Route of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Drug Delivery Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Application
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Drug Delivery Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Application
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Drug Delivery Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Application
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By End User

10. South America Drug Delivery Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Application
  • 10.2.2. By Route of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Drug Delivery Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Application
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Drug Delivery Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Application
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Drug Delivery Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Application
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Drug Delivery Devices Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Pfizer Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. F. Hoffmann-La Roche Ltd
• 15.4. Johnson and Johnson
• 15.5. Bayer AG
• 15.6. Becton, Dickinson and Company
• 15.7. Altaris Capital Partners, LLC
• 15.8. Holozymes Inc. (Antares Pharma Inc.)
• 15.9. GlaxoSmithKline PLC
• 15.10. Teva Pharmaceutical Industries Ltd

16. Strategic Recommendations

17. About Us & Disclaimer